conference logo slide...european halo effect peripheral arterial disease (pad or pvd) 26% metabolic...
TRANSCRIPT
![Page 1: CONFERENCE LOGO SLIDE...European Halo Effect Peripheral Arterial Disease (PAD or PVD) 26% Metabolic Syndrome 23% Hypertension plus one risk factor 25% Hypertension 22% CAD or CEVD](https://reader036.vdocuments.us/reader036/viewer/2022081614/5fcbbf25971e8f4fdc4363aa/html5/thumbnails/1.jpg)
The Problem
◼ Cardiovascular prevention trials are large, long and expensive
• 10,000+ patients
• Years of patient follow-up
• € 100,000,000+ development cost
◼ Many patient groups-data from one group may not be relevant to others
How can MR help design the clinical program to maximize revenue and minimize development time and cost?
![Page 2: CONFERENCE LOGO SLIDE...European Halo Effect Peripheral Arterial Disease (PAD or PVD) 26% Metabolic Syndrome 23% Hypertension plus one risk factor 25% Hypertension 22% CAD or CEVD](https://reader036.vdocuments.us/reader036/viewer/2022081614/5fcbbf25971e8f4fdc4363aa/html5/thumbnails/2.jpg)
Opportunity for MR
◼ MR traditionally develops target product profile
◼ High cost of CV clinical development leads to a new MR opportunity
• ID patient populations• Trade off revenue and cost
![Page 3: CONFERENCE LOGO SLIDE...European Halo Effect Peripheral Arterial Disease (PAD or PVD) 26% Metabolic Syndrome 23% Hypertension plus one risk factor 25% Hypertension 22% CAD or CEVD](https://reader036.vdocuments.us/reader036/viewer/2022081614/5fcbbf25971e8f4fdc4363aa/html5/thumbnails/3.jpg)
The Approach
How do cardiologists think about CV risk?
30 Key Opinion Leader Interviews
How will MDs extrapolate data?
Web survey: 200 cardiologists & PCPs
How to trade off revenue and costs?
Patient Rx versus clinical cost and time
![Page 4: CONFERENCE LOGO SLIDE...European Halo Effect Peripheral Arterial Disease (PAD or PVD) 26% Metabolic Syndrome 23% Hypertension plus one risk factor 25% Hypertension 22% CAD or CEVD](https://reader036.vdocuments.us/reader036/viewer/2022081614/5fcbbf25971e8f4fdc4363aa/html5/thumbnails/4.jpg)
Objectives
◼ Quantify the revenue impact of:• Registration studies (baseline)
• Four different patient populations
◼ Incremental impact of:• Biomarker studies
• Surrogate endpoint studies
15 scenarios in all
![Page 5: CONFERENCE LOGO SLIDE...European Halo Effect Peripheral Arterial Disease (PAD or PVD) 26% Metabolic Syndrome 23% Hypertension plus one risk factor 25% Hypertension 22% CAD or CEVD](https://reader036.vdocuments.us/reader036/viewer/2022081614/5fcbbf25971e8f4fdc4363aa/html5/thumbnails/5.jpg)
Peripheral
Arterial Disease
(PAD or PVD)
Cerebrovascular
Disease
(CEVD)
Coronary
Artery
Disease
(CAD)
CV Risk Stratification
BMI > 30
Abdominal Fat
> 140 systolic
or
> 90 diastolic
LDL > 160 mg/dL
HDL < 40 mg/dL
Obesity Dyslipidemia Hypertension SmokingType II
DiabetesAge
Age:
M > 65, 55, 45
F >75, 65, 55
PTCA
CABG
ACS
Post MI
Unstable
Angina
Single
Risk
Factors
Stroke
Carotid
Disease
Documented
Carotid
Narrowing
Intermittent
ClaudicationPrevious
Event
Multiple Risk Factors including
“Metabolic Syndrome”
Inc
rea
sin
g R
isk
of
CV
Eve
nt
or
De
ath
![Page 6: CONFERENCE LOGO SLIDE...European Halo Effect Peripheral Arterial Disease (PAD or PVD) 26% Metabolic Syndrome 23% Hypertension plus one risk factor 25% Hypertension 22% CAD or CEVD](https://reader036.vdocuments.us/reader036/viewer/2022081614/5fcbbf25971e8f4fdc4363aa/html5/thumbnails/6.jpg)
Type II
Diabetes
Coronary
Artery Disease
(CAD)
Cerebrovascular
Disease
(CEVD)
Peripheral
Arterial Disease
(PAD or PVD)
CV Risk Stratification - Qualitative Risk
Model Schematic
or or
CAD or CEVD or PVD w/ DM
Secondary
PreventionPost-Primary
Event
Primary
PreventionPre-Primary
Event
Inc
rea
sin
g R
isk
of
CV
Eve
nt
or
De
ath
BMI > 30
Abdominal Fat
> 140 systolic
or
> 90 diastolic
LDL > 160 mg/dL
HDL < 40 mg/dL
Obesity Dyslipidemia Hypertension SmokingType II
DiabetesAge
Age:
M > 65, 55, 45
F >75, 65, 55
PTCA
CABG
ACS
Post MI
Unstable
Angina
Metabolic
Syndrome
Risk
Factors
Stroke
Carotid
Disease
Documented
Carotid
Narrowing
Intermittent
Claudication
Hypertension
Plus One Other
Risk Factoror
or
![Page 7: CONFERENCE LOGO SLIDE...European Halo Effect Peripheral Arterial Disease (PAD or PVD) 26% Metabolic Syndrome 23% Hypertension plus one risk factor 25% Hypertension 22% CAD or CEVD](https://reader036.vdocuments.us/reader036/viewer/2022081614/5fcbbf25971e8f4fdc4363aa/html5/thumbnails/7.jpg)
Eligible US patients slightly outnumber
those in Europe
Patients Eligible for Treatment (MM)
1.0
2.0
3.0
4.0
5.0
6.0
CV+DM DM CAD CEVD PVD HBP+1 Met. Syn. HBP
Millio
ns o
f P
ati
en
ts
U.S.
Europe
![Page 8: CONFERENCE LOGO SLIDE...European Halo Effect Peripheral Arterial Disease (PAD or PVD) 26% Metabolic Syndrome 23% Hypertension plus one risk factor 25% Hypertension 22% CAD or CEVD](https://reader036.vdocuments.us/reader036/viewer/2022081614/5fcbbf25971e8f4fdc4363aa/html5/thumbnails/8.jpg)
◼ A leading pharmaceutical company will offer an alternative
add-on therapy for CV patients who have documented CV
disease or are at risk for CV disease and currently receiving
standard clinical therapy.
◼ The product has the following characteristics:
• Novel mechanism
• Oral, once daily in tablet form
• Reduces events/revascularization procedures by 25%
• No increase in adverse drug events
• No additional side effects or monitoring
• No clinically significant drug-drug interactions with
commonly co-prescribed medications
• Price comparable to Lipitor
Product Profile
![Page 9: CONFERENCE LOGO SLIDE...European Halo Effect Peripheral Arterial Disease (PAD or PVD) 26% Metabolic Syndrome 23% Hypertension plus one risk factor 25% Hypertension 22% CAD or CEVD](https://reader036.vdocuments.us/reader036/viewer/2022081614/5fcbbf25971e8f4fdc4363aa/html5/thumbnails/9.jpg)
Physician Comments on Product Profile
◼ First in class-cardiologists had little basisfor comparison with alternatives
◼ Interviewees expect mortality data inaddition to “events”
◼ Cardiologists need good safety data
![Page 10: CONFERENCE LOGO SLIDE...European Halo Effect Peripheral Arterial Disease (PAD or PVD) 26% Metabolic Syndrome 23% Hypertension plus one risk factor 25% Hypertension 22% CAD or CEVD](https://reader036.vdocuments.us/reader036/viewer/2022081614/5fcbbf25971e8f4fdc4363aa/html5/thumbnails/10.jpg)
Type II Diabetes32%
CerebrovascularDisease (CEVD)
58%
Coronary Artery Disease (CAD)
42%
US Halo Effect
Peripheral Arterial Disease (PAD or PVD)
35%
Metabolic Syndrome27%
Hypertension plus one risk factor
30%
Hypertension26%
CAD or CEVD or PVDw/ Type II Diabetes
45%
Regulatory approval
6.7 MM total patients
45%
32%
45%
28%
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
CV + DM DM CADCEVD/PAD
PrimaryPrevention
Pe
rce
nt
of
Pa
tie
nts
0.7
1.0
2.42.6
0.5
1.0
1.5
2.0
2.5
CV + DM DM
Pa
tie
nts
(M
M)
CADCEVD/PAD
PrimaryPrevention
![Page 11: CONFERENCE LOGO SLIDE...European Halo Effect Peripheral Arterial Disease (PAD or PVD) 26% Metabolic Syndrome 23% Hypertension plus one risk factor 25% Hypertension 22% CAD or CEVD](https://reader036.vdocuments.us/reader036/viewer/2022081614/5fcbbf25971e8f4fdc4363aa/html5/thumbnails/11.jpg)
Type II Diabetes25%
CerebrovascularDisease (CEVD)
55%
Coronary Artery Disease (CAD)
32%
European Halo Effect
Peripheral Arterial Disease (PAD or PVD)
26%
Metabolic Syndrome23%
Hypertension plus one risk factor
25%
Hypertension22%
CAD or CEVD or PVDw/ Type II Diabetes
42%
5.5 MM total patients
42%
25%
38%
23%
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
CV + DM DM CADCEVD/PAD
PrimaryPrevention
Pe
rce
nt
of
Pa
tie
nts
0.90.6
2.2
1.8
0.5
1.0
1.5
2.0
2.5
CV + DM DM
Pa
tie
nts
(M
M)
CADCEVD/PAD
PrimaryPrevention
Regulatory approval
![Page 12: CONFERENCE LOGO SLIDE...European Halo Effect Peripheral Arterial Disease (PAD or PVD) 26% Metabolic Syndrome 23% Hypertension plus one risk factor 25% Hypertension 22% CAD or CEVD](https://reader036.vdocuments.us/reader036/viewer/2022081614/5fcbbf25971e8f4fdc4363aa/html5/thumbnails/12.jpg)
Biomarker Effect
Type II Diabetes41% (36%)
CerebrovascularDisease (CEVD)
47% (38%)
Coronary Artery Disease (CAD)66% (65%)
Peripheral Arterial Disease (PAD or PVD)
47% (38%)
Metabolic Syndrome37% (29%)
Hypertension plus one risk factor
38% (32%)
Hypertension34% (28%)
CAD or CEVD or PVDw/ Type II Diabetes
54% (50%)
Regulatory approval
Epidemiological study: shown elevated disease biomarker
7.7MM to 8.7 MM total patients
0.71.1
3.02.8
0.5
1.0
1.5
2.0
2.5
Pa
tie
nts
(M
M)
0.8
1.3
3.23.43.0
CV + DM DM CAD/CEVD/PAD Primary Prev.
50%
36%
47%
30%
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
CV + DM DM CAD/CEVD/PAD Primary Prev.
Pe
rce
nt
of
Pa
tie
nts 54%
41%
53%
36%
55%
CAD App & Epi
CAD App + Epi
![Page 13: CONFERENCE LOGO SLIDE...European Halo Effect Peripheral Arterial Disease (PAD or PVD) 26% Metabolic Syndrome 23% Hypertension plus one risk factor 25% Hypertension 22% CAD or CEVD](https://reader036.vdocuments.us/reader036/viewer/2022081614/5fcbbf25971e8f4fdc4363aa/html5/thumbnails/13.jpg)
Surrogate Effect
Type II Diabetes37% (36%)
CerebrovascularDisease (CEVD)
46% (44%)
Coronary Artery Disease (CAD)71% (68%)
Peripheral Arterial Disease (PAD or PVD)
42% (39%)
Metabolic Syndrome33% (31%)
Hypertension plus one risk factor
36% (34%)
Hypertension30% (29%)
CAD or CEVD or PVDw/ Type II Diabetes
61% (54%)
Regulatory approval
Epidemiological study: shown elevated disease biomarker
Study has shown improvement in surrogate endpoint
7.9MM to 8.4 MM total patients
54%
36%
50%
31%
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
CV + DM DM CAD/CEVD/PAD Primary Prev.
Pe
rce
nt
of
Pa
tie
nts 61%
37%
53%
33%
55%
CAD App + Epi
CAD App + Epi + Surr in CV+DM
1.20.9
3.4
2.4
0.5
1.0
1.5
2.0
2.5
Pa
tie
nts
(M
M)
1.3
3.6
2.5
3.0
CV + DM DM CAD/CEVD/PAD Primary Prev.
0.9
![Page 14: CONFERENCE LOGO SLIDE...European Halo Effect Peripheral Arterial Disease (PAD or PVD) 26% Metabolic Syndrome 23% Hypertension plus one risk factor 25% Hypertension 22% CAD or CEVD](https://reader036.vdocuments.us/reader036/viewer/2022081614/5fcbbf25971e8f4fdc4363aa/html5/thumbnails/14.jpg)
Primary Hypertension Treatment#
Type II Diabetes
US 56% (53%)EU 45% (50%)
CerebrovascularDisease (CEVD)
US 64% (53%)EU 53% (50%)
Coronary Artery Disease (CAD)
US 79% (53%)EU 75% (50%)
Survey Responses
Client Estimate*
* Prescribing for secondary prevention patients with elevated BP is much higher (e.g., 85% for CAD patients with elevated BP in the U.S.).
# Physician responses for secondary prevention patients are weighted 2:1 cardiologist to PCP; for primary prevention, patients weighted 1:5 cardiologist to PCP.
Peripheral Arterial Disease (PAD or PVD)
US 63% (53%)EU 51% (50%)
Metabolic Syndrome
US 53% (69%)EU 51% (43%)
Hypertension plus one risk factor
US 66% (69%)EU 62% (43%)
Hypertension
US 62% (69%)EU 57% (43%)
CAD or CEVD or PVDw/ Type II Diabetes
US 82% (53%)EU 81% (50%)
![Page 15: CONFERENCE LOGO SLIDE...European Halo Effect Peripheral Arterial Disease (PAD or PVD) 26% Metabolic Syndrome 23% Hypertension plus one risk factor 25% Hypertension 22% CAD or CEVD](https://reader036.vdocuments.us/reader036/viewer/2022081614/5fcbbf25971e8f4fdc4363aa/html5/thumbnails/15.jpg)
Halo Effect Summary
A B C D E F G H I J K L M N O
Scenario
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
16.0
18.0
20.0
Pati
en
ts (
MM
)
Indication Halo Biomarker Surrogate
![Page 16: CONFERENCE LOGO SLIDE...European Halo Effect Peripheral Arterial Disease (PAD or PVD) 26% Metabolic Syndrome 23% Hypertension plus one risk factor 25% Hypertension 22% CAD or CEVD](https://reader036.vdocuments.us/reader036/viewer/2022081614/5fcbbf25971e8f4fdc4363aa/html5/thumbnails/16.jpg)
Revenue Present Value versus Clinical Cost
Scenario A
Scenario B
Scenario C
Scenario D
Scenario E
Scenario F
Scenario G
Scenario H
Scenario I
Scenario J
Scenario K
Scenario L
Scenario M
Scenario N
Scenario O
Cost versus Revenue PV Index
50
60
70
80
90
100
$150 $200 $250 $300 $350
Clinical Development Cost
Re
ve
nu
e P
V I
nd
ex
(0
-1
00
)
![Page 17: CONFERENCE LOGO SLIDE...European Halo Effect Peripheral Arterial Disease (PAD or PVD) 26% Metabolic Syndrome 23% Hypertension plus one risk factor 25% Hypertension 22% CAD or CEVD](https://reader036.vdocuments.us/reader036/viewer/2022081614/5fcbbf25971e8f4fdc4363aa/html5/thumbnails/17.jpg)
Outcome◼ Phase IIB program to support the “Blue”
registration plan, which maximizes revenues and saves:• $80 million
• 1 year to market
◼ Technique recently expanded to marketed products-predicting impact of new(Phase IV) clinical trials• Client sponsored
• Competitor sponsored
![Page 18: CONFERENCE LOGO SLIDE...European Halo Effect Peripheral Arterial Disease (PAD or PVD) 26% Metabolic Syndrome 23% Hypertension plus one risk factor 25% Hypertension 22% CAD or CEVD](https://reader036.vdocuments.us/reader036/viewer/2022081614/5fcbbf25971e8f4fdc4363aa/html5/thumbnails/18.jpg)
Conclusions◼ MR spending early in development can
save $ and time
◼ “Rocket science” is understanding clinical trial trade offs, not MR tools
◼ Web enables more complex research• Faster and better, not
• Faster and cheaper